Dernières nouvelles pour Ensysce Biosciences (NASDAQ:ENSC) Stock

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

Social media accounts that track flights of celebrities and business figures, including Tesla CEO Elon Musk have been suspended on Threads and Instagram, two platforms owned by Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). The accounts had previously been banned on X since Musk bought the platform.
What Happened: Jack Sweeney, best known for launching a jet tracking account of Musk's flights on X, shared Tuesday that he had 38 accounts that track various figures suspended on Threads and Instagram without warning.
"Today brings a sense of déjà vu," Sweeney <a href="https://x.com/Jxck_Sweeney">said </a>in the letter.
Sweeney questioned Meta's rules and transparency as he hadn't changed anything and the accounts were previously okay to operate.
"What makes this more troubling is that I've received no communication from Meta — no warnings, no explanation. Reporters have reached out to Meta for clarification, but so far, there's been silence. This situation reflects poorly on Meta."
The recent suspensions come after Sweeney had a Taylor Swift jet tracker account <a href="https://www.benzinga.com/general/entertainment/24/02/36973423/taylor-swift-sends-cease-and-desist-to-student-for-tracking-her-private-jet">suspended 10 months ago</a>, but others remained and operated "just fine."
Sweeney went on to question Meta's oversight system in his letter.
"I can't even appeal these suspensions through Meta's Oversight Board. This lack of transparency makes Meta's actions even more concerning."
The jet tracker questioned in his letter the timing of accounts being shut down.
"I'm still unsure if this decision came directly from Meta or not, but it's worth noting that, just yesterday, Elon Musk supporters were <a href="https://x.com/cb_doge/status/1848190507215692232">vocal </a>about the suspension of @taylorswiftjets while @elonmuskjets remained active."
In another X post, Sweeney questioned why "tracking public info can be so controversial" and how he hadn't violated the rules from Meta in past years.
"Suddenly they care about something they haven't for years?"
Among the suspended accounts include flight tracking on Meta CEO Mark Zuckerberg, Jeff Bezos, Kylie Jenner and Kim Kardashian.
An account <a href="https://www.benzinga.com/news/22/12/30194852/elon-musks-jet-tracker-is-back-on-twitter-but-with-a-difference">that shares information</a> on Musk's flights a day later and abides by new X rules remains <a href="https://x.com/ElonJetNextDay">active </a>on the platform.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: Sweeney previously clashed with Musk after his X account shared flight details of the billionaire. After previously promising to keep the account active, Musk shut it down after acquiring X, which was then known as Twitter.
"Ironically, Elon Musk, who once criticized Twitter for its lack of free speech, is now using the very same techniques — shadow-banning jet-tracking account and blocking links to public information that tracks his jet. It's just a different form of suppression, rather than outright bans," Sweeney said Tuesday.
Meta said the decision came from its Oversight Board, based on a recommendation from early 2022, according to a report from <a href="https://www.bloomberg.com/news/articles/2024-10-22/meta-bans-accounts-tracking-private-jets-for-zuckerberg-musk?sref=TBDibEcD">Bloomberg</a>. The recommendation was to remove "private residential information" from the site even if publicly available.
"Given the risk of physical harm to individuals, and in keeping with the independent Oversight Board's recommendation, we've disabled these accounts for violating our privacy policy," a Meta spokesperson said in a statement, Bloomberg reported.
Musk <a href="https://www.benzinga.com/general/entertainment/24/02/36974802/taylor-swift-right-to-be-concerned-elon-musk-calls-celebrity-jet-tracker-awful-human-being">previously called Sweeney</a> "an awful human being" when Swift and her team threatened legal action against the account creator.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/22/06/27752857/why-the-teen-who-tracks-elon-musks-jet-agreed-to-stop-monitoring-mark-cuban">Why The Teen Who Tracks Elon Musk&#8217;s Jet Agreed To Stop Monitoring Mark Cuban</a></li>
</ul>
Photo: Elon Musk via Shutterstock

Entertainment

News

Social Media

Elon Musk Jet Tracker Suspended On Threads, Instagram: 'This Situation Reflects Poorly On Meta'

JPMorgan analysts said they are encouraged by mobile gaming trends and expect spending on consoles to improve next year driven by a strong game slate. 
The research firm updated its coverage on video game companies, including Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), Applovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) and Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) ahead of their <a href="https://www.benzinga.com/general/gaming/24/10/41319267/us-gaming-market-sees-7-spending-decline-in-august-madden-nfl-25-debut-a-bright-spot">third-quarter earnings reports. </a>
Roblox: JPMorgan pointed to Roblox as one of the firm's favorite names in the video game industry due to its combination of healthy engagement trends, ads/commerce business ramping and free cash flow seen as compounding at 30% through 2027. 
The analysts also highlighted data suggesting Roblox's daily active users (DAUs) are <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41257301/roblox-usage-climbs-among-us-teens-analyst-raises-target-to-54">tracking above </a>estimates and potential upside to third-quarter bookings. JPMorgan maintained its Overweight rating on Roblox shares and raised the price target from $50 to $51 ahead of its earnings release on Oct. 31. 
Read Next: <a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a>
Applovin: JPMorgan highlighted Applovin as the leading in-app monetization platform for mobile gaming companies. The firm spoke with industry contacts who reported Applovin accounted for between 40% and 60% of their user acquisition spending. 
The analysts expect strong third-quarter results from the company due to stable growth in the mobile gaming industry, but remained neutral on the stock as the firm awaits evidence that Applovin can scale beyond gaming. The firm maintained its Neutral rating on Applovin, but raised the price target considerably, from $57 to $160. 
Electronic Arts: The firm pointed to EA's position as the largest pure-play game publisher in the industry that "increasingly favors scale and the largest IP" portfolio. The firm maintained its Neutral rating and $155 price target and said it is looking for "more consistent execution on non-sports titles" from <a href="https://www.benzinga.com/general/gaming/24/10/41365831/plants-vs-zombies-3-servers-shut-down-as-ea-plans-major-overhaul">the company</a>. 
Electronic Arts will be the first from the group to report its quarterly results on Oct. 29 after the market close. The Street estimates the company will report earnings of $2.02 per share on revenue of $2.036 billion, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Gaming

Analyst Ratings

Movers

RBLX

JPMorgan Updates Video Game Industry Coverage, Taps Roblox As Top Pick

Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) .

Guidance

VLRS

Volaris expects EBITDAR margin 36% (Prior 32% to 34%), ASM growth (YoY) 13% (prior 14%) and CAPEX of $400 million.

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $20 to $12.

Price Target

EDIT

Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $12

The spin-off and merger of Berry&#39;s HHNF Business with Glatfelter are expected to be completed on November 4, 2024, subject to the satisfaction or waiver of the closing conditions for the transaction. As previously announced, in connection with the merger, Glatfelter will effect a reverse stock split and change its name to Magnera Corporation (&quot;Magnera&quot;).

BERY

Berry Global Sets Record Date Of Close Of Business On November 1, 2024 For Proposed Spin-off Of Its HHNF Business

Jones Trading analyst Jason Weaver maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Buy and maintains $10.25 price target.

AGNC

Jones Trading Maintains Buy on AGNC Investment, Maintains $10.25 Price Target

Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.24 by 4.17 percent. This is a 20.69 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $131.782 million which missed the analyst consensus estimate of $134.246 million by 1.84 percent. This is a 1.86 percent increase over sales of $129.372 million the same period last year.

Earnings

Earnings Misses

Brandywine Realty Tr Q3 2024 FFO $0.23 Misses $0.24 Estimate, Sales $131.782M Miss $134.246M Estimate

Macquarie analyst Tim Nollen maintains Interpublic Gr of Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) with a Neutral and maintains $31 price target.

Macquarie Maintains Neutral on Interpublic Gr of Cos, Maintains $31 Price Target

Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) lowers FY2024 FFO guidance from $0.91-0.96 to $0.89-0.92 vs $0.92 analyst estimate..

Brandywine Realty Tr Lowers FY2024 FFO Guidance from $0.91-0.96 to $0.89-0.92 vs $0.92 Est

On Tuesday,&nbsp;Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) reported third-quarter revenue of $9.91 billion, up 8.4% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41453988/marlboro-maker-philip-morris-highlights-strong-q3-performance-on-higher-prices-issues-upbeat-annual" rel="noreferrer noopener">consensus of $9.69 billion</a>.
Net revenues increased by 11.6% on an organic basis, mainly reflecting a favorable pricing variance, primarily due to higher combustible tobacco pricing, and a favorable volume/mix, mainly driven by higher smoke-free product volume.
Outlook: Philip Morris raised its fiscal year 2024 adjusted EPS outlook&nbsp;to $6.45-$6.51 from&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39908836/tobacco-company-philip-morris-lights-up-q2-earnings-surpass-estimates-raises-2024-eps-forecast" rel="noreferrer noopener">prior guidance of $6.33 – $6.45</a> versus the consensus of $6.41.
Goldman Sachs believes that the management&#8217;s raised guidance is attainable, citing strong momentum in iQOS, improvements in ZYN&#8217;s out-of-stock levels, growth in the smoke-free segment, and the steady performance of Philip Morris&#8217; traditional cigarette business.
Goldman reiterates the Buy rating for Philip Morris.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41030763/philip-morris-analyst-raises-forecasts-ahead-of-q3-earnings-but-consumer-elasticiti" rel="noreferrer noopener">Philip Morris Analyst Raises Forecasts Ahead Of Q3 Earnings, But &#8216;Consumer Elasticities Remain A Risk&#8217;</a>
The analyst is particularly optimistic about the significant progress in reducing ZYN out-of-stock in the U.S., aligning with insights from their recent Nicotine Nuggets Q3 Retailer Survey, which should help limit market share loss.
&#8220;Ultimately we believe management&#8217;s decision to raise guidance again this year is positive and suggests management has good visibility into its business,&#8221; the analyst writes.
The analyst says the third quarter results significantly exceeded expectations, and management raised its FY24 guidance for the third time this year.
Notably, they also increased dollar EPS growth projections, even with a larger anticipated currency headwind, highlighting the strong underlying momentum.
Price Action: PM stock is up 10.50% at $131.41 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41462536/nvidia-accelerates-global-growth-eyes-ai-chip-development-in-india-and-expansion-in-thailand" target="_blank" rel="noreferrer noopener">Nvidia Accelerates Global Growth, Eyes AI Chip Development in India and Expansion in Thailand</a></li>
</ul>
Photo via Shutterstock

Large Cap

Reiteration

Trading Ideas

General

Philip Morris' Raised Guidance Suggests Good Visibility: Goldman Sachs Analyst

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1200 to $1050.

REGN

Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1050

The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on October 23, 2024, under the ticker symbol &quot;LBGJ.&quot;

IPOs

LBGJ

Li Bang International Prices IPO Of 1.52M Ordinary Shares At 4.00 Per Ordinary Share

EBTC

Enterprise Bancorp Q3 EPS $0.80 Up From $0.79 YoY, Sales $44.16M Up From $42.99M YoY

The U.S. Securities and Exchange Commission (SEC) charged four major companies — Unisys Corp.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>), Avaya Holdings Corp., Check Point Software Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) and Mimecast — with making materially misleading public disclosures related to <a href="https://www.benzinga.com/topic/cybersecurity">cybersecurity risks and breaches</a>.
SEC argued these four companies downplayed the seriousness of the SolarWinds Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) Orion software supply chain attack in their filings, potentially misleading investors about the true impact of the breaches.
"As today's enforcement actions reflect, while public companies may become targets of cyberattacks, it is incumbent upon them to not further victimize their shareholders or other members of the investing public by providing misleading disclosures about the cybersecurity incidents they have encountered,"<a href="https://www.sec.gov/newsroom/press-releases/2024-174"> said</a> Sanjay Wadhwa, acting director of the SEC's Division of Enforcement.
Unisys, a major IT services provider, was hit with an additional charge for failing to implement proper disclosure controls and procedures. The company will pay a $4 million civil penalty, the highest among the four.
The SEC found that Unisys described cybersecurity risks as hypothetical in its public disclosures despite knowing that two SolarWinds-related breaches occurred, resulting in the exfiltration of gigabytes of data. According to the SEC, Unisys&#8217; disclosures were "materially misleading" partly due to its deficient internal controls.
Other fines include $1 million for Avaya, $995,000 for Check Point and $990,000 for Mimecast.
Avaya, a telecommunications firm, claimed the SolarWinds hackers accessed only a "limited number of email messages," while SEC findings revealed the cybercriminals accessed at least 145 files in Avaya's cloud file-sharing environment.
Check Point, an Israeli cybersecurity firm, allegedly minimized the breach by using vague descriptions of the cyber intrusions and their potential risks.
Mimecast, which specializes in cloud email and data security, was found to have underreported the extent of the attack by failing to disclose the type of code exfiltrated and the number of encrypted credentials compromised.
The SolarWinds hack was a major cyberattack in 2020, during which Russian state-sponsored hackers inserted malicious code into SolarWinds' Orion software. This &#8220;Sunburst&#8221; malicious code provided attackers with remote access to the systems of thousands of organizations, including private-sector firms such as Microsoft and FireEye and major U.S. government departments such as Homeland Security and Treasury.
Although the companies have not admitted to or denied the SEC&#8217;s findings, they have agreed to pay the fines and take corrective measures to strengthen their cybersecurity practices.
The SEC filed a lawsuit in October 2023, but this July U.S. District Judge Paul Engelmayer dismissed most of the accusations against SolarWinds, ruling that claims of defrauding investors were speculative.
Read Next:<a href="https://www.benzinga.com/news/large-cap/24/10/41465485/openai-appoints-former-uber-exec-as-compliance-officer-to-oversee-regulatory-issues"> </a> • <a href="https://www.benzinga.com/news/large-cap/24/10/41465485/openai-appoints-former-uber-exec-as-compliance-officer-to-oversee-regulatory-issues">OpenAI Appoints Former Uber Exec As Compliance Officer To Oversee Regulatory Issues</a>

Photo: Shutterstock

Government

Regulations

Legal

Global

Tech

CHKP

SEC Charges Four Companies Over SolarWinds Hacks, Issues Millions In Penalties

There will be many storylines for the 2024 National Basketball Association season, including new faces in new places, the return of LeBron James for a 22nd season and the arrival of James' son Bronny James <a href="https://www.benzinga.com/general/sports-betting/24/07/39678086/bronny-james-to-win-nba-rookie-of-the-year-summer-league-debut-not-scaring-away-bettors-he">in the league.</a>
NBA Opening Games: The 2024 NBA season kicks off with two matchups Tuesday, Oct. 23 featuring <a href="https://www.benzinga.com/m-a/24/07/39605195/going-out-on-top-boston-celtics-for-sale-after-nba-title-large-contracts-handed-to-star-players">four playoff teams from last season.</a>
The New York Knicks at Boston Celtics will air at 7:30 p.m. ET on TNT and the Minnesota Timberwolves at Los Angeles Lakers will air at 10 p.m. ET on TNT.
The two opening games mark the start of the final season of TNT's coverage of the league, with parent company Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) losing out to others in a new rights package that will<a href="https://www.benzinga.com/general/entertainment/24/07/39733479/nba-fans-rejoice-new-76b-deal-from-espn-amazon-nbc-will-bring-games-seven-days-a-week"> kick off next season.</a>
The Celtics won last year's NBA championship, with the team dominant from the start of the season to the end and favored to win the title many times throughout the season. In the 2024 NBA Playoffs, the Celtics lost only three games in four playoff series.
The Timberwolves were the number three seed in the Western Conference and lost in the Conference Finals to the Dallas Mavericks. The Knicks were the number two seed in the Eastern Conference and lost in the Conference Semifinals to the Indiana Pacers. The Lakers were the number seven seed in the Western Conference and lost in the first round to the Denver Nuggets.
The Celtics are favored by six points Tuesday night against the Knicks and the Timberwolves are favored by one point against the Lakers according to betting odds from sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>).
Read Also: <a href="https://www.benzinga.com/general/education/24/10/41302910/why-mark-cuban-stepped-back-from-mavericks-ownership-his-kids-dont-need-all-that-abuse">Why Mark Cuban Stepped Back From Mavericks Ownership: His Kids Don&#8217;t Need &#8216;All That Abuse&#8217;</a>
<h3 class="wp-block-heading">LeBron And Bronny James Bets</h3>
One of the tipoff games features the debut of Bronny James in the NBA. In 2024, Bronny was drafted 55th overall by the Lakers — the same team his father had played for in the past six seasons.
Bronny James is a popular betting option to win Rookie of the Year, despite long odds. At DraftKings, Bronny James had odds of +25,000 to win the award, which would turn a $1 bet into a profit of $250.
At FanDuel, a unit of Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), Bronny has odds of +50,000 to win Rookie of the Year.
In the NBA preseason, Bronny <a href="https://www.espn.com/nba/story/_/id/41878872/bronny-james-scores-17-points-lakers-preseason-finale-vs-warriors">struggled </a>in the first five games with eight total points scored on 4-20 shooting, including 0-7 for three-point attempts. In the preseason finale, Bronny James had 17 points, shooting 7-17 from the field.
As Benzinga previously reported, history isn't on Bronny's side. Only three second-round picks have ever won the Rookie of the Year award. Malcom Brogdon (36th overall pick) was the last to accomplish the feat in 2017. The other two winners happened in the 1960s.
LeBron averaged 25.7 points, 7.3 rebounds and 8.3 assists last season versus career averages of 27.8 points, 6.8 rebounds and 8.8 assists.
LeBron has odds of +15,000 to win the NBA MVP for the season, which would be his fifth time winning.
On Tuesday, DraftKings lists the over/under on LeBron James for points at 24.5 and there is no line for Bronny James points. There is a betting market for the combined points for LeBron and Bronny with 28 points or more at +13t5 and 30 points or more combined at +195.
FanDuel has several special betting markets on Bronny, including the rookie having his first made field goal assisted by his dad paying at odds of +250 and Bronny's first assist being on a made shot by his dad paying at odds of +200.
The betting platform also offers betting on what Bronny's first made basket type will be, scoring 20 points or more in any NBA game, having a double-double in any NBA game and other player props.
NBA Championship Odds: The four teams that kick things off Tuesday night are all among the favorites to win the 2025 NBA Championship for the 2024 season.
The Knicks, who are owned by publicly traded Madison Square Garden Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) completed a trade to land NBA superstar Karl-Anthony Towns ahead of the season, which improved their odds of winning the championship.
Here are the current betting odds to win the NBA championship, with odds from July in parentheses:
<ul>
<li>Boston Celtics: +310 (+295)</li>
<li>Oklahoma City Thunder: +650 (+850)</li>
<li>New York Knicks: +800 (+950)</li>
<li>Denver Nuggets: +950 (+850)</li>
<li>Minnesota Timberwolves: +1,000 (+1,000)</li>
<li>Philadelphia 76ers: +1,000 (+800)</li>
<li>Dallas Mavericks: +1,000 (+1,000)</li>
<li>Milwaukee Bucks: +1,400 (+1,100)</li>
<li>Los Angeles Lakers: +3,000 (+3,000)</li>
<li>Phoenix Suns: +3,000 (+3,500)</li>
</ul>
The top 10 favorites to win the NBA title haven't changed, only the order of the betting odds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/10/41304838/nba-legend-shaq-admitted-that-he-never-voted-in-presidential-election-until-2020-as-he-urged-oth">NBA Legend Shaq Admitted That He &#8216;Never Voted&#8217; In Presidential Election Until 2020 As He Urged Others To Register: &#8216;One Thing I Never Like To Do Is Be A Hypocrite&#8217;</a></li>
</ul>
Image: Shutterstock

Sports Betting

Sports

DKNG

FLUT

MSGS

Bronny James NBA Debut: Betting Odds As LeBron And Son Take The Court Together For First Time

Wells Fargo analyst Steven Cahall downgrades Interpublic Gr of Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) from Equal-Weight to Underweight and lowers the price target from $28 to $26.

Downgrades

Wells Fargo Downgrades Interpublic Gr of Cos to Underweight, Lowers Price Target to $26

Citigroup analyst Jason Bazinet maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $155 to $185.

Citigroup Maintains Buy on AppLovin, Raises Price Target to $185

Citigroup analyst Ariel Rosa maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Buy and raises the price target from $294 to $302.

Citigroup Maintains Buy on Norfolk Southern, Raises Price Target to $302

Citigroup analyst Judy Zhang downgrades UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) from Buy to Sell and raises the price target from $5 to $5.5.

TIGR

Citigroup Downgrades UP Fintech Holding to Sell, Raises Price Target to $5.5

Maxim Group analyst Jason McCarthy maintains AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) with a Buy and lowers the price target from $2 to $1.

Maxim Group Maintains Buy on AIM ImmunoTech, Lowers Price Target to $1

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Fisker (NYSE:<a href="https://investorplace.com/stock-quotes/fsr-stock-quote/">FSR</a>) stock is moving on Monday after the electric vehicle (EV) company announced that it has secured an <a href="https://investors.fiskerinc.com/news/news-details/2024/Fisker-Announces-Receipt-of-Financing-Commitment-of-Up-to-150-Million-and-Provides-Business-Update/default.aspx">additional $150 million in funding</a>.



According to a press release from Fisker, the company&rsquo;s new funding comes from the holder of its 2025-dated convertible notes. It&rsquo;s also worth noting that this funding is being split into four tranches.



Fisker also mentions that this funding is only available if it meets certain conditions. Chief among these is the filing of the company&rsquo;s Form 10-K for 2023.



Investors will keep in mind that Fisker still has inventory from 2023 on hand. Combined with what has been produced in 2024, it has an excess inventory of over $200 million. The company is pausing production for six weeks starting today to align its inventory.



It&rsquo;s also worth mentioning that Fisker is still in talks with a large automaker for an investment. This has it hoping for funding to develop an EV platform with the manufacturer.



<h2>How This Affects FSR Stock Today</h2>



Despite news of the additional financing, shares of FSR stock are still falling on Monday. This has the stock down 12% this morning.



That drop for FSR stock comes alongside some 136 million shares changing hands. That&rsquo;s a massive surge in trading volume compared to the company&rsquo;s average of about 67 million shares.



Investors searching for more of the latest stock market stories are in luck!



We have all of the hottest stock market news ready to go on Monday! A few examples include what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Xpeng&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/xpev-stock-quote/">XPEV</a>) and Ensysce Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) stock moving today. All of that information is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/nio-stock-ceo-william-li-says-second-gen-nio-phone-is-underway/">NIO Stock: CEO William Li Says Second-Gen Nio Phone Is Underway</a></li>



<li><a href="https://investorplace.com/2024/03/xpev-stock-alert-xpeng-pops-on-news-of-cheaper-ev-brand/">XPEV Stock Alert: Xpeng Pops on News of Cheaper EV Brand</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/fsr-stock-the-150-million-reason-fisker-shares-are-moving-today/">FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today

Ensysce Biosciences GAAP EPS of -$0.55

Ensysce Biosciences regains Nasdaq compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ensysce Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) just reported results for the first quarter of 2024.<ul><li>Ensysce Biosciences reported earnings per share of -55 cents. This was above the analyst estimate for EPS of -93 cents.</li><li>The company reported revenue of $305,722.</li><li>This was 23.57% worse than the analyst estimate for revenue of $400,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ensc-stock-earnings-ensysce-biosciences-for-q1-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ensysce Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) just reported results for the second quarter of 2024.<ul><li>Ensysce Biosciences reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -39 cents.</li><li>The company reported revenue of $181,797.</li><li>This was 39.40% worse than the analyst estimate for revenue of $300,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ensc-stock-earnings-ensysce-biosciences-for-q2-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024

Ensysce Biosciences GAAP EPS of -$0.22 beats by $0.11

Ensysce wins $14M federal grant for lead pain therapy

Voxx International Corp., Trinity Biotech Plc, and Ensysce Biosciences are the 3 Penny Stocks to watch on August 29, based on&nbsp;TipRanks' Penny ...

Comments

Ensysce Biosciences

Actualités

Dernières nouvelles pour Ensysce Biosciences (NASDAQ:ENSC) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL